BioCentury | Nov 10, 2020
Finance

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

...with at least two programs in pivotal studies. Its telitacicept (RC18), a fusion protein targeting BLyS...
BioCentury | Nov 7, 2020
Product Development

Amgen’s adaptive solution to lupus

...a master protocol for chronic pain.TARGETSBAFF (TNFSF13B; BLyS...
BioCentury | Oct 23, 2020
Emerging Company Profile

Be Bio: bringing the B to cell therapy

...which they engineered plasma B cells that could secrete physiological doses of Factor IX and BLyS...
BioCentury | Aug 22, 2020
Emerging Company Profile

Luminary: turning cell engineering tools into therapies

...necrosis factor receptor superfamily member 13bTNFSF13B (BAFF; BlyS...
...– TNF superfamily member 13b Sandi Wong Luminary Therapeutics Inc. BLyS...
BioCentury | Jul 7, 2020
Deals

July 7 Quick Takes: Luminary-Case Western partner on BLyS-targeting CAR T; plus Dragonfly-BMS, HiberCell-Biothera and Biogen-Mass Eye and Ear

...Luminary, Case Western partner on CAR T against BLyS Minneapolis-based Luminary Therapeutics Inc. gained an option...
...Therapeutics Inc. gained an option from Case Western Reserve University to exclusively license a novel BLyS...
...developing non-viral cell therapies for cancer and autoimmune disorders. Its lead program, LMY-920, is a BLyS-targeting...
BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

...disease leads to inflammation that affects kidney function. Post-hoc analyses of trial data suggested the BLyS...
...also soon see a shift in the treatment landscape (see “Three Late-Stage Wins” ). Targets BLyS...
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

...JAMA Neurology, Neurology, clinicaltrials.gov Targets AChE - acetylcholinesterase AChR - Acetylcholine receptor BAFF (TNFSF13B) - BLyS...
BioCentury | Nov 15, 2019
Product Development

Lupus makes leaps with three good pieces of news

...containing TACI, a TNF receptor superfamily member, fused to an antibody Fc segment; it targets BLyS...
...displays data across the primary endpoints from each study. Source: ACR Abstracts; published study Targets BLyS...
BioCentury | Nov 13, 2019
Clinical News

Three late-stage wins shift the clinical landscape in SLE

...placebo arm. The therapy was well tolerated during the 48-week Phase IIb trial. Telitacicept binds BLyS...
...from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), the only approved molecularly targeted therapy for SLE, also targets BLyS...
...Tumor necrosis factor ligand superfamily member 13 Lauren Martz and Karen Tkach Tuzman, Associate Editors AstraZeneca plc Idorsia Ltd. AutoImmune BLyS...
BioCentury | Jul 19, 2019
Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

...erythematosus (SLE). The human mAb against BLyS is the only biologic approved for SLE. Targets: BLyS...
Items per page:
1 - 10 of 284